AASLD2016[1807]乙型肝炎表面抗原滴度是一个很好的指标 恩替卡

StephenW

1807
Hepatitis B surface antigen titer is a good indicator of
durable viral response after off-treatment of entecavir
for chronic hepatitis B
Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park,
Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim,
Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um;
korea university medical center, Seoul si, Korea (the Republic of)
Background/Aims: Definite guideline for stopping antiviral therapy
for chronic hepatitis B (CHB) is not clarified yet. Previous
studies suggested that HBsAg titer is correlated with covalently
closed circular DNA. Therefore, HBsAg titer might be a good
indicator for off-treatment. This study was performed to determine
the relationship between HBsAg titer and CHB relapse
after off-treatment of entecavir (ETV). Methods: Patients in whom
ETV was discontinued after serum HBV with or without HBeAg
clearance for more than 12 months and who measured HBsAg
titer at off-treatment were enrolled. HBV DNA reactivation was
defined as increase of serum HBV DNA level >2000 IU/mL,
while CHB relapse was defined as HBV DNA reactivation and
increase of serum ALT level >2XULN. Results: Forty-four patients
were enrolled. Age was 44.6±11.4 years and 28 patients
(63.6%) were men. Baseline HBeAg was positive 25 patients
(56.8%) and serum HBV DNA level was 6.8±1.3 log10 IU/mL.
ETV was discontinued after 34.7±19.0 months of treatment.
In HBeAg-positive CHB patients, ETV was discontinued after
37.0±20.2 months of treatment, which was 31.0±19.5 and
23.4±16.1 months after serum HBV DNA and HBeAg clearance,
respectively. In HBeAg-negative CHB patients, ETV was
discontinued after 31.6±17.4 months of treatment, which was
27.1±17.7 months after serum HBV DNA clearance. HBsAg
titer at off-treatment was 3.0±1.0 log10 IU/mL, which was <2,
2~3, and >3 log10 IU/mL in 5 (11.4%), 11 (25.0%), and 28
(63.6%) patients, respectively. After off-treatment, HBV DNA
reactivated in 38.7% and 66.2% and CHB was relapsed
in 4.7% and 42.3% at 6 and 12 months after off-treatment,
respectively. HBsAg titer at off-treatment was significantly
associated with HBV DNA reappearance (P=0.010) and CHB
relapse (P=0.010). Conclusion: HBsAg titer at off-treatment is
closely related with HBV reactivation and CHB relapse. HBsAg
titer is considered as an excellent indicator of durable viral
response after off-treatment.
Disclosures:
Kwan Soo Byun - Grant/Research Support: Gilead, BMS
The following people have nothing to disclose: Han Ah Lee, Yeon Seok Seo,
Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul
Jung, Ji Hoon Kim, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um

StephenW

AASLD2016 [1807]乙型肝炎表面抗原滴度是一个很好的指标
恩替卡韦治疗后持久的病毒反应
为慢性乙型肝炎
乙型肝炎表面抗原滴度是一个很好的指标
恩替卡韦治疗后持久的病毒反应
为慢性乙型肝炎
Han Ah Lee，Yeon Seok Seo，Seung Woon Park，Sang Jung Park，
Tae Hyung Kim，Sang Jun Suh，Young Kul Jung，Ji Hoon Kim，
Hyung Joon Yim，Jong Eun Yeon，Kwan Soo Byun，Soon Ho Um;
韩国大学医疗中心，韩国（共和国）
背景/目的：停止抗病毒治疗的明确指南
为慢性乙型肝炎（CHB）尚未澄清。以前
研究表明HBsAg滴度与共价相关
闭合环形DNA。因此，HBsAg滴度可能是一个好的
指示剂。进行该研究以确定
HBsAg滴度与CHB复发之间的关系
在对恩替卡韦（ETV）进行治疗后。方法：
ETV在血清HBV伴有或不伴有HBeAg后停止
清除超过12个月和测量HBsAg
离体治疗的滴度。 HBV DNA再激活
定义为血清HBV DNA水平增加> 2000 IU / mL，
而CHB复发定义为HBV DNA再激活
血清ALT水平升高> 2XULN。结果：44例患者
登记。年龄44.6±11.4岁，28例
（63.6％）为男性。基线HBeAg阳性25例
（56.8％），血清HBV DNA水平为6.8±1.3log10 IU / mL。
ETV在治疗34.7±19.0个月后停止。
在HBeAg阳性CHB患者中，ETV后停止
治疗37.0±20.2个月，为31.0±19.5和
23.4±16.1个月后血清HBV DNA和HBeAg清除，
分别。在HBeAg阴性CHB患者中，ETV为
在治疗31.6±17.4个月后中止，
27.1±17.7个月后血清HBV DNA清除率。 HBsAg
脱离处理的滴度为3.0±1.0log 10 IU / mL，其<2，
2〜3，> 5log10 IU / mL（11.4％），11（25.0％）和28
（63.6％）患者。离体后，HBV DNA
再激活38.7％和66.2％，CHB复发
在离开治疗后6和12个月时分别为4.7％和42.3％
分别。脱离治疗的HBsAg滴度显着
与HBV DNA复发（P = 0.010）和CHB相关
复发（P = 0.010）。结论：离体治疗的HBsAg滴度为
与HBV再激活和CHB复发密切相关。 HBsAg
效价被认为是持久病毒的优良指标
治疗后的反应。
披露：
Kwan Soo Byun - 资助/研究支持：Gilead，BMS
以下人士没有透露：韩亚李，Yeon Seok Seo，
Seung Woon Park，Sang Jung Park，Tae Hyung Kim，Sang Jun Suh，Young Kul
Jung，Ji Hoon Kim，Hyung Joon Yim，Jong Eun Yeon，Soon Ho Um